NEW YORK (CNN/Money) - Drugmakers Pfizer Inc. and Vicuron Pharmaceuticals Inc. said Sunday that Pfizer's proposed $1.9 billion acquisition of Vicuron has cleared a federal antitrust review, and will be completed Wednesday.

The companies said the Hart-Scott-Rodino antitrust review waiting period expired without action by the federal government

Vicuron (Research) says it is currently working on two major drugs, including an antifungal agent.

Pfizer (Research) shares closed Friday at $26.33, down 18 cents.